208 related articles for article (PubMed ID: 28726431)
1. [What has the GLAGOV clinical study shown?].
Murín J
Vnitr Lek; 2017; 63(5):329-332. PubMed ID: 28726431
[TBL] [Abstract][Full Text] [Related]
2. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
[TBL] [Abstract][Full Text] [Related]
3. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ
Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224
[TBL] [Abstract][Full Text] [Related]
4. Results of the GLAGOV trial.
Nissen SE; Nicholls SJ
Cleve Clin J Med; 2017 Dec; 84(12 Suppl 4):e1-e5. PubMed ID: 29281604
[TBL] [Abstract][Full Text] [Related]
5. Effect of Evolocumab on Coronary Plaque Composition.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJP; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Honda S; Shishikura D; Scherer DJ; Borgman M; Brennan DM; Wolski K; Nissen SE
J Am Coll Cardiol; 2018 Oct; 72(17):2012-2021. PubMed ID: 30336824
[TBL] [Abstract][Full Text] [Related]
6. Implications of GLAGOV study.
Nicholls SJ; Puri R
Curr Opin Lipidol; 2017 Dec; 28(6):465-469. PubMed ID: 28937411
[TBL] [Abstract][Full Text] [Related]
7. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
[TBL] [Abstract][Full Text] [Related]
8. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies.
Gragnano F; Calabrò P
Atherosclerosis; 2018 Feb; 269():219-228. PubMed ID: 29407597
[TBL] [Abstract][Full Text] [Related]
9. Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH).
Han Y; Ren L; Fei X; Wang J; Chen T; Guo J; Wang Q
Atherosclerosis; 2024 Apr; 391():117471. PubMed ID: 38493669
[TBL] [Abstract][Full Text] [Related]
10. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study FOURIER].
Murín J
Vnitr Lek; 2017; 63(6):411-414. PubMed ID: 28840737
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
13. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
[TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
15. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Cardiovasc Drugs Ther; 2016 Jun; 30(3):297-304. PubMed ID: 26936841
[TBL] [Abstract][Full Text] [Related]
16. Atheroma progression in hyporesponders to statin therapy.
Kataoka Y; St John J; Wolski K; Uno K; Puri R; Tuzcu EM; Nissen SE; Nicholls SJ
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):990-5. PubMed ID: 25722430
[TBL] [Abstract][Full Text] [Related]
17. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
19. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
20. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.
Nicholls SJ; Kataoka Y; Nissen SE; Prati F; Windecker S; Puri R; Hucko T; Aradi D; Herrman JR; Hermanides RS; Wang B; Wang H; Butters J; Di Giovanni G; Jones S; Pompili G; Psaltis PJ
JACC Cardiovasc Imaging; 2022 Jul; 15(7):1308-1321. PubMed ID: 35431172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
